Bicycle Therapeutics Plc (BCYC)

$23.6

+1.4

(+6.31%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $22.23
    $23.61
    $23.60
    downward going graph

    5.81%

    Downside

    Day's Volatility :5.83%

    Upside

    0.02%

    downward going graph
  • $12.54
    $28.20
    $23.60
    downward going graph

    46.86%

    Downside

    52 Weeks Volatility :55.53%

    Upside

    16.31%

    downward going graph

Returns

PeriodBicycle Therapeutics PlcSector (Health Care)Index (Russel 2000)
3 Months
9.74%
4.9%
0.0%
6 Months
-3.31%
5.8%
0.0%
1 Year
0.0%
16.5%
0.0%
3 Years
-46.76%
20.3%
-20.1%

Highlights

Market Capitalization
1.5B
Book Value
$12.68
Earnings Per Share (EPS)
-3.77
Wall Street Target Price
39.27
Profit Margin
0.0%
Operating Margin TTM
-498.31%
Return On Assets TTM
-15.17%
Return On Equity TTM
-30.24%
Revenue TTM
39.6M
Revenue Per Share TTM
0.9
Quarterly Revenue Growth YOY
-17.9%
Gross Profit TTM
-67.1M
EBITDA
-176.8M
Diluted Eps TTM
-3.77
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.13
EPS Estimate Next Year
-3.5
EPS Estimate Current Quarter
-1.1
EPS Estimate Next Quarter
-1.17

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Bicycle Therapeutics Plc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 66.4%

Current $23.60
Target $39.27

Company Financials

FY18Y/Y Change
Revenue
7.1M
↑ 246.41%
Net Income
-21.8M
↑ 34.36%
Net Profit Margin
-306.14%
↑ 483.13%
FY19Y/Y Change
Revenue
13.8M
↑ 93.4%
Net Income
-30.6M
↑ 40.11%
Net Profit Margin
-221.78%
↑ 84.36%
FY20Y/Y Change
Revenue
10.4M
↓ 24.72%
Net Income
-51.0M
↑ 66.66%
Net Profit Margin
-490.95%
↓ 269.17%
FY21Y/Y Change
Revenue
11.7M
↑ 12.58%
Net Income
-66.8M
↑ 30.99%
Net Profit Margin
-571.25%
↓ 80.3%
FY22Y/Y Change
Revenue
14.5M
↑ 23.65%
Net Income
-112.7M
↑ 68.69%
Net Profit Margin
-779.35%
↓ 208.1%
FY23Y/Y Change
Revenue
27.0M
↑ 86.52%
Net Income
-180.7M
↑ 60.28%
Net Profit Margin
-669.72%
↑ 109.63%
Q1 FY23Q/Q Change
Revenue
4.9M
↑ 53.72%
Net Income
-39.1M
↑ 30.31%
Net Profit Margin
-797.88%
↑ 143.34%
Q2 FY23Q/Q Change
Revenue
11.4M
↑ 132.78%
Net Income
-42.6M
↑ 9.06%
Net Profit Margin
-373.81%
↑ 424.07%
Q3 FY23Q/Q Change
Revenue
5.4M
↓ 53.04%
Net Income
-49.9M
↑ 17.12%
Net Profit Margin
-932.32%
↓ 558.51%
Q4 FY23Q/Q Change
Revenue
5.3M
↓ 0.39%
Net Income
-49.1M
↓ 1.6%
Net Profit Margin
-921.01%
↑ 11.31%
Q1 FY24Q/Q Change
Revenue
19.5M
↑ 266.14%
Net Income
-26.5M
↓ 45.93%
Net Profit Margin
-136.01%
↑ 785.0%
Q2 FY24Q/Q Change
Revenue
9.4M
↓ 51.99%
Net Income
-39.9M
↑ 50.13%
Net Profit Margin
-425.3%
↓ 289.29%
FY18Y/Y Change
Total Assets
81.6M
↑ 10.3%
Total Liabilities
151.5M
↑ 24.98%
FY19Y/Y Change
Total Assets
110.2M
↑ 35.0%
Total Liabilities
17.0M
↓ 88.78%
FY20Y/Y Change
Total Assets
161.2M
↑ 46.24%
Total Liabilities
65.7M
↑ 286.51%
FY21Y/Y Change
Total Assets
479.8M
↑ 197.73%
Total Liabilities
133.5M
↑ 103.28%
FY22Y/Y Change
Total Assets
410.6M
↓ 14.42%
Total Liabilities
139.8M
↑ 4.71%
FY23Y/Y Change
Total Assets
595.3M
↑ 44.99%
Total Liabilities
224.4M
↑ 60.49%
Q1 FY23Q/Q Change
Total Assets
428.8M
↑ 4.43%
Total Liabilities
185.6M
↑ 32.76%
Q2 FY23Q/Q Change
Total Assets
454.2M
↑ 5.92%
Total Liabilities
234.1M
↑ 26.09%
Q3 FY23Q/Q Change
Total Assets
638.7M
↑ 40.63%
Total Liabilities
222.7M
↓ 4.88%
Q4 FY23Q/Q Change
Total Assets
595.3M
↓ 6.79%
Total Liabilities
224.4M
↑ 0.79%
Q1 FY24Q/Q Change
Total Assets
547.1M
↓ 8.1%
Total Liabilities
191.1M
↓ 14.85%
Q2 FY24Q/Q Change
Total Assets
1.1B
↑ 93.25%
Total Liabilities
183.5M
↓ 3.95%
FY18Y/Y Change
Operating Cash Flow
-26.1M
↑ 1742.97%
Investing Cash Flow
-1.2M
↑ 6.56%
Financing Cash Flow
25.4M
↓ 56.06%
FY19Y/Y Change
Operating Cash Flow
-28.6M
↑ 9.72%
Investing Cash Flow
-1.6M
↑ 31.11%
Financing Cash Flow
58.4M
↑ 129.81%
FY20Y/Y Change
Operating Cash Flow
-17.8M
↓ 37.83%
Investing Cash Flow
-1.2M
↓ 22.83%
Financing Cash Flow
62.8M
↑ 7.53%
FY21Y/Y Change
Operating Cash Flow
-14.8M
↓ 16.84%
Investing Cash Flow
-2.0M
↑ 69.17%
Financing Cash Flow
320.7M
↑ 410.36%
FY22Y/Y Change
Operating Cash Flow
-86.1M
↑ 482.07%
Investing Cash Flow
-19.0M
↑ 835.32%
Financing Cash Flow
6.7M
↓ 97.91%
Q1 FY23Q/Q Change
Operating Cash Flow
-46.4M
↑ 53.13%
Investing Cash Flow
-277.0K
↓ 80.87%
Financing Cash Flow
2.7M
↓ 53.84%
Q2 FY23Q/Q Change
Operating Cash Flow
34.1M
↓ 173.47%
Investing Cash Flow
-277.0K
↑ 0.0%
Financing Cash Flow
12.3M
↑ 352.24%
Q3 FY23Q/Q Change
Operating Cash Flow
-1.0M
↓ 103.01%
Investing Cash Flow
-502.0K
↑ 81.23%
Financing Cash Flow
234.6M
↑ 1808.81%

Technicals Summary

Sell

Neutral

Buy

Bicycle Therapeutics Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc
8.08%
-3.31%
0.0%
-46.76%
109.43%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.33%
8.11%
21.28%
85.63%
257.49%
Novo Nordisk A/s
Novo Nordisk A/s
-12.25%
-9.71%
24.92%
138.38%
343.21%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
9.22%
72.73%
52.35%
34.04%
250.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.09%
12.2%
25.77%
150.7%
163.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc
NA
NA
NA
-3.13
-0.3
-0.15
NA
12.68
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc
Buy
$1.5B
109.43%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
257.49%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
343.21%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
250.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.62%
32.84
-4.74%

Insights on Bicycle Therapeutics Plc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 19.51M → 9.37M (in $), with an average decrease of 52.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -26.54M → -39.85M (in $), with an average decrease of 50.1% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 52.3% return, outperforming this stock by 52.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 34.0% return, outperforming this stock by 80.8%

Institutional Holdings

  • Baker Bros Advisors LP

    13.62%

  • Deep Track Capital, LP

    5.06%

  • RA Capital Management, LLC

    3.27%

  • FCPM III SERVICES BV

    3.08%

  • Armistice Capital, LLC

    2.86%

  • Westfield Capital Management Company, LP

    2.21%

Company Information

bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun

Organization
Bicycle Therapeutics Plc
Employees
284
CEO
Dr. Kevin Lee M.B.A., Ph.D.
Industry
Biotechnology

Discover More

FAQs